Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 37 tulemused
Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60)
Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Cutaneous metastases from visceral carcinomas are relatively uncommon, with an overall incidence ranging from 0.7 to 9%. Diagnosis of scalp metastases usually escapes clinicians and dermatologists due to the fact that these metastases are mimicking other benign dermatological conditions. Herein, we
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A 45-year-old woman who suffered from left breast cancer, 8 cm in diameter, with skin invasion and axillary lymph node involvement but no distant metastasis, underwent neoadjuvant chemotherapy. FEC100 consisting of 5-FU (500 mg/m(2)), epirubicin (100 mg/m(2)) and cyclophosphamide (500 mg/m(2)), were
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer. Many patients receive dexamethasone but complain of insomnia, anxiety/agitation, and indigestion. The aim was to determine if patients receiving
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-dense Doxorubicin/cyclophosphamide.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
UNASSIGNED
Dose-dense chemotherapy (DD-CT) is a preferred (neo) adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent meta-analysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules.
Gastric Metastasis Mimicking Linitis Plastica 20 Years after Primary Breast Cancer. A Case Report.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Breast cancer metastases to the gastrointestinal tract are rare, with a median time interval from the diagnosis of the primary tumor to metastasis up to 7 years. The stomach is the most frequent metastatic site and invasive lobular carcinoma is the type with the highest affinity to the digestive
[Primary hyperparathyroidism as a cause of hypercalcemia in a patient with breast cancer].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Hypercalcemia associated with breast cancer arises either from metastatic bone disease or from paraneoplastic secretion of parathyroid hormone-related peptide. We report a female 69-year-old patient with invasive intraductal breast cancer and hypercalcemia (3,4 mmol/l) referred to endocrinologist.
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Several studies have evaluated the clinical effectiveness of endocrine therapy alone in women aged 70 years or over and who are fit for surgery.
OBJECTIVE
To identify and review the evidence from randomised trials comparing primary endocrine therapy (endocrine therapy alone) to surgery,
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A fatal gastric perforation secondary to ulcerated metastasis in undiagnosed breast cancer: pathological aspects and review of literature.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The authors describe a fatal case of gastric perforation secondary to an ulcerated metastasis in a woman with undiagnosed breast cancer. The 48-year-old woman, with no significant medical history, presented with weight loss, persistent dyspepsia and pain in the epigastric and mesogastric region. She
Panchakola Reduces Oxidative Stress in MCF-7 Breast Cancer and HEK293 Cells.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A large number of studies have proven the efficacy of ayurveda in the field of health and wellness. Panchakola, an ayurvedic formulation, is a general health tonic primarily used to cure fever, inflammation, pain, indigestion, and so on. We investigated effects of panchakola on oxidative stress in
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
In patients with HER2-positive metastatic breast cancer (MBC), combined treatment of herceptin (H) and chemotherapy (CT) improves time to progression, response rates and survival compared with CT alone.
METHODS
We evaluated the safety and efficacy of weekly Docetaxel combined with weekly
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18 F-FES PET/CT imaging
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background: Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from
The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethamine.HCL, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine.HCl (DPPE) is a diphenylmethane analog of tamoxifen that antagonizes the intracellular binding of histamine to growth-regulatory sites, a proportion of which represents P450 enzymes, in microsomes and nuclei. We previously reported increased
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
Many women with hormone receptor-positive breast cancer discontinue effective aromatase inhibitor (AI) treatment due to joint symptoms.
METHODS
We conducted a single-arm, open-label, phase II study evaluating glucosamine-sulfate (1,500 mg/day) + chondroitin-sulfate (1,200 mg/day) for 24
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
